A Study To Assess A Novel Form Of Cataract Treatment Using The Non-Invasive LEDINBIO Proof-Of-Concept Device

Cataract Clinical Trial

Official title:

A Study To Assess A Novel Form Of Cataract Treatment Using The Non-Invasive LEDINBIO Proof-Of-Concept Device

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04569318
• Other study ID #: EB-14-LAT
• Status: Terminated
• Phase: N/A
• Start date: October 19, 2020
• Est. completion date: September 9, 2021

Study information

• Verified date: September 2021
• Source: Edinburgh Biosciences Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single arm proof-of-concept trial to evaluate the safety and efficacy of the LEDINBIO PoC Device in the treatment of cataract.

Description:

Single arm, single site proof-of-concept trial to evaluate the safety and efficacy of the LEDINBIO PoC Device, with 8 x 15-minute twice-weekly treatments and 3 month safety follow-up, in the treatment of cataract.

Only one of the subject's eyes will be treated during the study. In addition, spectral data (fluorescent emission) will be collected using the device to monitor the progress of the treatment, and to determine the suitability of these measurements for future clinical diagnoses

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: September 9, 2021
• Est. primary completion date: August 19, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Subject diagnosed with nuclear sclerotic (NS) lens opacities cataract, LOCS III grade 1 to 3 (moderate), as confirmed by the Investigator

2. Subject aged between 55 and 85 years of age (inclusive) at the time of consent

3. Best corrected visual acuity (BCVA) of 0.3 or worse due to cataract only

4. Subject whom the medical health history has been reviewed by the Investigator and medical records do not contraindicate the participation to the study

5. Subject who is judged suitable for the study after ophthalmic examination carried out by the Investigator

6. Be able and willing to follow instructions, including participation in all study assessments and visits, according to the opinion of the investigator - including being able to sit upright for at least 20 mins (duration of the treatment)

Exclusion Criteria:

1. Subject unable to give voluntary written informed consent, is unlikely to cooperate or is legally incompetent, including subjects who are institutionalised by court or official order, or in a dependency relationship with sponsor, testing centre or investigator

2. Subject who had been clinically diagnosed with any eye diseases which may impact upon the treatment, or the subject's ability to be assessed after treatment

3. Subject with shallow anterior chamber

4. Subject who have had a fluorescence angiogram or any use of fluorescein within the last 3 days

5. Subject presenting eye infection or eye damage in either eye

6. Subject routinely using contact lenses

7. Planned replacement of crystalline lens with intraocular lens (IOL) implant within the planned study period

8. Any condition which could interfere with the subject's ability to comply with the study including participation in all study assessments and visits.

9. Subject who had undergone a treatment using photodynamic drugs within the last 30 days. (Including but not limited to methylene blue, toluidine blue, Visudyne®, Foscan, Photofrin or 5-aminolevulinic acid/ALA)

10. Subject diagnosed with any other health condition which, in the opinion of the Investigator, would pose a safety risk to the subject by participating in the study, or may interfere with or jeopardise the study evaluation, procedures or completion

11. Subject currently receiving treatment in another investigational study or has completed another investigational study within the last 30 days

12. Females who are pregnant or lactating

13. Females who are of childbearing potential (menses within the last 12 months) and not taking adequate contraceptive precautions are excluded from the trial. Females of childbearing potential taking acceptable contraceptive precautions may be included.

Related Conditions & MeSH terms

• Cataract

Intervention

Device:
• Treatment Beam
One of the subject's eyes will be treated with the 415 nm treatment beam (20mW) up to 8 times for 15 minutes.

Locations

Country	Name	City	State
Latvia	Dr.Solomatina Acu Centrs	Riga

Sponsors (2)

Lead Sponsor	Collaborator
Edinburgh Biosciences Ltd	Onorach Clinical

Country where clinical trial is conducted

Latvia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: assessed by changes in the Local Ocular Tolerability (LOT) Visual Analogue Scale (VAS)	Assessment of safety defined as changes in the LOT VAS. A self-administered 7-item (foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision, photophobia) 100 mm VAS on which 0 means no symptoms and 100 means the worst possible discomfort. VAS Ocular Tolerability Overall score is the mean of all VAS Ocular Tolerability symptom scores per visit per eye	20 weeks
Primary	Efficacy: Cataract Grade	Assessment of efficacy, defined as treating cataract assessed using Lens Opacities Classification System (LOCS) III. Higher scores mean a worse outcome.	5 weeks
Secondary	Change in cataract severity	Assessed using Objective Scatter Index (OSI) using Visiometrics HD Analyser. Higher scores mean a worse outcome.	5 weeks
Secondary	Change in visual acuity	Assessed using LogMAR (Logarithm of the Minimum Angle of Resolution) scale. Higher scores mean a worse outcome.	5 weeks
Secondary	Change in light scatter	Assessed using Visiometrics HD Analyser. Higher scores mean a worse outcome.	5 weeks
Secondary	Change in functional impairment due to cataract	Assessed using VF-14 (Visual Function Index) questionnaire data. Higher scores mean a better outcome.	5 weeks